It has been shown that type 2 innate immunity reduces skin inflammation caused by Demodex. Decreased type 2 cytokine expression is observed in patients with Demodex-associated rhinophyma, affecting follicles of the nose, while activation of group 2 innate lymphoid cells (ILC2s), interleukin-13 (IL-13), and its receptor, IL-4Ra-IL-13Ra1, limit proliferation and spread of mites (75). Here, IL13 is linked to dermatitis.